Regorafenib Post-marketing Surveillance
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for colorectal cancer.

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice.

A total of 1,250 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.
Colorectal Neoplasms
DRUG: Regorafenib (Stivarga, BAY73-4506)
Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib, Up to 6 months|Number of patients with serious adverse events(SAEs) from the first administration of regorafenib., up to 6 months
Number of pateints with ADRs in subpopulations, Up to 6 months|Number of patients with SAEs in supopulations, Up to 6 months|Overall survival (OS), Up to 12 months|Overall survival in subpopulations, Up to 12 months|Time to treatment failure (TTF), Up to 12 months|Time to Treatment failure in subpopulations, Up to 12 months|Tumor response assessed by RECIST or physicians own evaluation, RECIST: Response Evaluation Criteria In Solid Tumors, Up to 6 months
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for colorectal cancer.

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice.

A total of 1,250 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.